NPH snags Avecia Pharmaceuticals

October 2005
Chemical Market Reporter;10/31/2005, Vol. 268 Issue 15, p7
Trade Publication
Reports on the acquisition of Great Britain-based custom synthesis and manufacturing firm Avecia Pharmaceuticals by Mumbai, India-based Nicholas Piramal India Ltd. Amount involved in the acquisition deal; Plan of Avecia to put the proceeds towards a deficit in the company's pension fund; Businesses of Avecia Pharmaceuticals included in the deal.


Related Articles

  • NPIL broadens its global reach. Jarvis, Lisa // Chemical Market Reporter;11/14/2005, Vol. 268 Issue 17, p20 

    Reports on the efforts of Nicholas Piramal India Ltd. (NPIL), a Mumbai-based chemical manufacturer, in broadening its global business operations by entering into several acquisition agreements with other chemical manufacturers. Implication of the acquisition of Great Britain-based company Avecia...

  • Nicholas Piramal to spin off. Desai, Suresh Thakur // Chemical Business;May/Jun98, Vol. 12 Issue 5/6, p95 

    Reports on the approval by shareholders of Nicholas Piramal of the spin-off of the glass and bulk drug units.

  • Nicholas Piramal net rises by 23%. Desai, Suresh Thakur // Chemical Business;May/Jun98, Vol. 12 Issue 5/6, p95 

    Reports on the financial performance of Nicholas Piramal India Ltd. in the fiscal period 1997-98.

  • PHARMACEUTICALS & FINE CHEMICALS.  // Chemical Week;3/9/2009, Vol. 171 Issue 7, p25 

    This section offers news briefs concerning the pharmaceutical industry. Minted International has been acquired for around $40 million by Piramal Pharmaceutical, an Indian pharmaceutical company. Research and Markets reported that China is the primary choice for pharmaceutical outsourcing, which...

  • Piramal to acquire Pfizer facility. Mirasol, Feliza // Chemical Market Reporter;6/19/2006, Vol. 269 Issue 24, p6 

    The article reports on the plan of Nicholas Piramal India Ltd. to acquire Pfizer's Morpeth manufacturing facility on an asset purchase basis. The acquisition will increase the revenue of NPIL by 350 million dollars over the next five years. NPIL has been buying up manufacturing operations...

  • Rhodia Deal the Latest in a String of API Acquisitions by Indian Firms. Scott, Alex // Chemical Week;1/18/2006, Vol. 168 Issue 2, p25 

    The article reports on acquisition deals in the pharmaceutical and fine chemicals industries as of January 18, 2006. The purchase of Rhodia Pharma Solutions by custom active pharmaceutical ingredients (API) producer Shasun Chemicals and Drugs is the latest in a wave of API acquisitions by Indian...

  • Fine Chemical Firms Plan Multimillion-Dollar Investments. Scott, Alex // Chemical Week;2/28/2007, Vol. 169 Issue 7, p29 

    The article reports on the Informex fine and specialty chemicals expo held in San Francisco, California in February 2007. The event was awash with companies planning to install fine chemical manufacturing capacity. According to Cambrex it will spend $30 million-$60 million within the next three...

  • Innovations. O'Driscoll, Catherine // ICIS Chemical Business;6/26/2006, Vol. 1 Issue 25, p43 

    The article presents news briefs on the global chemical industry. Researchers at the University of Florence in Italy have discovered a new form of solid carbon dioxide that promises to be useful for making ultra-hard glass or coatings for microelectronic devices. Nicholas Piramal has announced...

  • The beginning of the end for EU specialities? Baker, John // European Chemical News;10/31/2005, Vol. 83 Issue 2169, p5 

    This article reports on the effort of Asian producers to acquire assets in Europe as of October 2005. It was said that such efforts were made to gain market access and technology. According to reports, Avecia revealed it has struck a deal to sell its pharmaceutical custom synthesis business in...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics